Pfizer Stock - consensus view stays cautious after recent setbacks
18.06.2026 - 17:37:47 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 17:36 CET. Details in the imprint.
Pfizer (US7170811035) faces a subdued Wall Street stance after several recent clinical and regulatory setbacks across its pipeline. Analysts largely stick to Hold-equivalent ratings and only cautiously adjust their models following disappointing obesity and oncology news, as reflected in current consensus data from major brokers.
All news and analysis on Pfizer stock
Stay on top of Pfizer's latest pipeline updates, earnings reports and analyst revisions with our curated overview of news and price data.
What recent news implies for consensus
Pfizer has had to confront a notable setback in its obesity ambition after ending development of oral GLP-1 candidate danuglipron in its twice-daily form because of tolerability issues, a decision outlined in a late 2023 update and repeatedly referenced in subsequent analyst notes.
The group also discontinued development of the anti-CTLA4 antibody feladilimab and other oncology programs in recent years, reinforcing a perception that the pipeline has yet to replace pandemic-era COVID revenue with sufficiently robust late-stage assets.
How analysts currently rate Pfizer
Across major houses tracked by MarketBeat, Pfizer stock carries an aggregate rating around Hold, with only a minority of Buy recommendations and a modest number of Sell calls, illustrating a cautious stance on the risk-reward profile.
The average 12-month price target in that compilation sits only moderately above the current share price, pointing to expected upside in the low double-digit percentage range, which is relatively muted for a large-cap pharma undergoing a strategic reset.
What the earnings estimates show
Current consensus earnings estimates embed sharp year-on-year declines from the pandemic peak, with 2026 EPS projections still well below the levels seen when COVID-19 vaccine Comirnaty and antiviral Paxlovid were at their height, according to broker models summarized by data providers.
Revenue expectations likewise indicate a step-down from 2021 and 2022, followed by only gradual growth as non-COVID products and new launches scale, underscoring the pressure on management to deliver pipeline progress and execute cost-saving measures.
Why sentiment remains restrained
Sentiment analysis platforms such as Adanos show only moderately positive buzz around Pfizer on social channels, with roughly half of recent posts skewing bullish and the remainder cautious or negative, reinforcing the impression of a divided investor base.
Against this backdrop, many analysts argue that while the valuation acknowledges much of the bad news, tangible proof of new growth engines in areas such as oncology, vaccines and metabolic disease is still required before ratings move decisively higher.
The product behind the stock
Pfizer generates revenue from a broad portfolio of prescription medicines and vaccines, including well-known products such as the pneumococcal vaccine Prevnar, anticoagulant Eliquis (shared with Bristol Myers Squibb), oncology therapies like Ibrance and COVID-19 treatments Comirnaty and Paxlovid.
Where the stock trades today
Pfizer shares (US7170811035) trade on the New York Stock Exchange at $25.92 as of 06/18/2026, 13:07 EDT.
Key facts on Pfizer stock
- Company: Pfizer Inc.
- ISIN: US7170811035
- WKN: 852009
- Ticker: PFE
- Venue: NYSE
- Price (as of 06/18/2026, 13:07 EDT): 25.92 USD
- Market cap: 147,890,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
